1 citations
,
October 2014 in “Annals of oncology” This case series found that paclitaxel and nab-paclitaxel may be safe and effective chemotherapy options for hemodialysis patients with unresectable advanced or recurrent gastric cancer.
April 2025 in “Biological and Clinical Sciences Research Journal” In this retrospective study conducted at Nishtar Hospital, nab-paclitaxel combined with radiotherapy provided similar survival outcomes to cisplatin in treating early-stage cervical cancer, with lower hematologic and gastrointestinal toxicity, though alopecia was more common.
October 2023 in “Indian Journal of Skin Allergy” This study discusses a rare case of subacute cutaneous lupus erythematosus induced by nab-paclitaxel, a complication scarcely reported in existing literature related to paclitaxel use.
141 citations
,
September 2016 in “European Journal of Dermatology” This review examines dermatological side effects of taxane chemotherapy reported in past studies and highlights the necessity for identifying and managing these conditions to maintain cancer patients' quality of life; it presents no new clinical results.
6 citations
,
December 2021 in “Journal of Cancer Research and Therapeutics” In this study, induction nab-paclitaxel plus cisplatin, combined with nimotuzumab and IMRT, followed by S-1 adjuvant chemotherapy, showed excellent survival benefits with tolerable toxicities for stage N3 nasopharyngeal carcinoma patients.